Showing 8831-8840 of 9897 results for "".
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Lumenis Unveiling New Laser Capability at ASLMShttps://practicaldermatology.com/news/20120413-lumenis_unveiling_new_laser_capability_at_aslms/2459826/Lumenis will unveil UltraPulse's new SCAAR FX CO2 laser treatment capability at the American Society for Laser Medicine and Surgery (ASLMS) annual meeting in Kissimmee, FL. Using up to 150mJoules per pulse, the high energy impact and precision o
- Warning for Blood Clot Risk Added to Drospirenone OCPshttps://practicaldermatology.com/news/20120411-warning_for_blood_clot_risk_added_to_drospirenone_ocps/2459827/The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred t
- Vichy Partners With timeRAZOR for Free iPhone, Android Apphttps://practicaldermatology.com/news/20120404-vichy_partners_with_timerazor_for_free_iphone_android_app/2459828/With the new timeRAZOR app, Vichy and timeRAZOR help keep users in the know on events occurring close to where they work, live, or plan to be. timeRAZOR pairs technologic components like geolocation with its own Massive Event Selection Engine, i
- Prostaglandin D2 A Potential New Target for Alopecia Therapyhttps://practicaldermatology.com/news/20120326-prostaglandin_d2_a_potential_new_target_for_alopecia_therapy/2459832/Prostaglandin D2 (PGD2) appears to inhibit hair growth in androgenetic alopecia (AGA) and may be potential target for its treatment, new research suggests (Sci Transl Med. 4(126):126ra34). Researchers show that PG
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459834/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459833/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b